Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma

Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma

PurposeBased on the efficacy data from the previous study of B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell injection, we further examined the delayed toxicity for 8 weeks after a single dose of BCMA CAR T-cell injection to observe possible toxic reactions.MethodsB-NDG mice...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jianmin Guo, Qiqi Wu, Hongjian Li, Chun Liang, Jinlong Dai, Shuren Zhang, Cailing Dai, Jishuai Zhang, Yuying Wen, Wei Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Immunology
Subjects:	multiple myeloma chimeric antigen receptor T cells immunotherapy B-cell maturation antigen cytokines delayed toxicity
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1435934/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Targeting BCMA in multiple myeloma: designs, challenges, and future directions
by: Yi Hu, et al.
Published: (2025-02-01)

Corrigendum: Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
by: Chengcheng Zhang, et al.
Published: (2025-01-01)

Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
by: Chengcheng Zhang, et al.
Published: (2023-05-01)

Hepatic T cell lymphoma after chimeric antigen receptor T cell therapy for myeloma
by: Joshua Mehr, et al.
Published: (2024-12-01)

Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer
by: Ernesto Lopez, et al.
Published: (2023-12-01)

A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
by: Wee-Joo Chng, et al.
Published: (2024-11-01)

The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer
by: Hao-Yu Tang, et al.
Published: (2025-01-01)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
by: Pavel Otáhal, et al.
Published: (2016-04-01)

Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
by: P. Joy Ho, et al.
Published: (2025-01-01)

CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies
by: Fang Wang, et al.
Published: (2025-02-01)

Targeting CEA in metastatic triple negative breast cancer with image-guided radiation followed by Fab-mediated chimeric antigen receptor (CAR) T-cell therapy
by: Eric Aniogo, et al.
Published: (2024-12-01)

Universal CAR cell therapy: Challenges and expanding applications
by: Ziyu Wu, et al.
Published: (2025-01-01)

Soluble factors released by peripheral blood-derived CAR-NK cells cause bystander myeloid cell activation
by: Supreet Khanal, et al.
Published: (2024-12-01)

Real‐world practitioner perceptions of CARTITUDE‐4 results for patients with previously treated multiple myeloma
by: Alexandrina Balanean, et al.
Published: (2024-12-01)

Unleashing the potential of a low CpG Passer transposon for superior CAR-T cell therapy
by: Jianyao Zeng, et al.
Published: (2025-02-01)

An integral membrane constitutively active heparanase enhances the tumor infiltration capability of NK cells
by: Sofia Liborio-Ramos, et al.
Published: (2025-12-01)

Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells
by: Yang Liu, et al.
Published: (2025-01-01)

Nano-immunotherapy for lung cancer
by: Yuting Lu, et al.
Published: (2023-03-01)

Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
by: Xu Yang, et al.
Published: (2024-12-01)

Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors
by: Jian Ding, et al.
Published: (2023-12-01)

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia
by: Tingting Yang, et al.
Published: (2025-01-01)

Optimized BCMA/CS1 bispecific TRuC-T cells secreting IL-7 and CCL21 robustly control multiple myeloma
by: Min Li, et al.
Published: (2024-12-01)

The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis
by: Jile Liu, et al.
Published: (2025-01-01)

Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024Keypoints
by: Bastian Engel, et al.
Published: (2025-02-01)

Modeling interaction of Glioma cells and CAR T-cells considering multiple CAR T-cells bindings
by: Runpeng Li, et al.
Published: (2023-03-01)

Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment
by: Liting Chen, et al.
Published: (2025-01-01)

Potent anti‐tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma
by: Felix Oden, et al.
Published: (2015-08-01)

New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
by: Yuanyuan Yang, et al.
Published: (2024-11-01)

CD8α Structural Domains Enhance GUCY2C CAR-T Cell Efficacy
by: Trevor R. Baybutt, et al.
Published: (2024-12-01)

Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells
by: Marat Khaliulin, et al.
Published: (2024-11-01)

Chimeric antigen receptor T-cell therapy in autoimmune diseases
by: Jie Liu, et al.
Published: (2024-11-01)

The Efficacy of Chimeric Antigen Therapy in Viral Infectious Diseases: A Systematic Review of Randomized Controlled Trials
by: Hossein Hatami, et al.
Published: (2024-12-01)

TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models
by: Christopher S. Hackett, et al.
Published: (2024-09-01)

Case report: CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B-related cirrhosis
by: Danqing Kong, et al.
Published: (2024-12-01)

A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells
by: Zhao Zhang, et al.
Published: (2025-01-01)

Efficient Predictor for Immunotherapy Efficacy: Detecting Pan‐Clones Effector Tumor Antigen‐Specific T Cells in Blood by Nanoparticles Loading Whole Tumor Antigens
by: Weibiao Zeng, et al.
Published: (2025-01-01)

Evaluation of CAR-T cell cytotoxicity against a prostate carcinoma model
by: A.Kh. Valiullina, et al.
Published: (2022-06-01)

High-affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells
by: Russell W. Cochrane, et al.
Published: (2024-12-01)

CAR’TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment
by: Karin Teppert, et al.
Published: (2024-06-01)